Markets:

Overview

News

Currencies

International

Treasuries

Castle Biosciences, Inc. - Common stock (NQ:CSTL)

36.05 -2.88 (-7.41%)

Streaming Delayed Price Updated: 12:01 PM EST, Feb 4, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Castle Biosciences, Inc. - Common stock

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Introduction of Innovative PCR-Based Detection Methods Surges Fueled by Pandemic and Other Diseases

February 18, 2022

Palm Beach, FL – February 18, 2022 – FinancialNewsMedia.com News Commentary – PCR testing and the COVID-19 diagnostic testing market has, unexpectantly, been growing at a substantial rate the past few...

Via FinancialNewsMedia

Topics Intellectual Property

Castle Biosciences to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on Monday, Feb. 28, 2022

February 14, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the 11th Annual SVB Leerink Global Healthcare Conference

February 07, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Collaborates with the National Cancer Institute to Link DecisionDx®-Melanoma Testing Data with SEER Registries’ Cutaneous Melanoma Cases

February 03, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Named a Winner of the 2022 Top Workplaces USA Award

February 02, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present Data at Maui Derm for Dermatologists 2022

January 24, 2022

From Castle Biosciences, Inc.

Via Business Wire

Recently Published Data Confirm DecisionDx®-SCC as a Significant and Independent Risk-Stratification Tool in Patients with Squamous Cell Carcinoma and One or More Risk Factors

January 13, 2022

From Castle Biosciences, Inc.

Via Business Wire

Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma

January 12, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2021 Results

January 10, 2022

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the 24th Annual Needham Growth Conference

December 28, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Completes Acquisition of Cernostics

December 06, 2021

From Castle Biosciences, Inc.

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For January 7, 2022 ↗

January 07, 2022

Upgrades According to Wolfe Research, the prior rating for CVR Energy Inc (NYSE:

Via Benzinga

Castle Biosciences Presents Data Reinforcing the Clinical Utility of Its DecisionDx® Dermatologic Portfolio

November 24, 2021

From Castle Biosciences, Inc.

Via Business Wire

Data Demonstrating DecisionDx®-Melanoma Was a Significant, Independent Predictor of Metastatic Recurrence in Stage I-III Cutaneous Melanoma Published in Future Oncology

November 19, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Named in Inc.’s First-Annual Best-Led Companies

November 17, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Named a 2021 Houston Chronicle Top Workplace

November 15, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

November 10, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Announces Third Quarter 2021 Results

November 08, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Releases Inaugural Environmental, Social and Governance (ESG) Report

November 08, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Publishes DecisionDx®-Melanoma Study on the Validation of the i31-GEP SLNB Artificial Intelligence Algorithm

November 05, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences’ Full DecisionDx® Portfolio of Dermatologic Tests to Be Interfaced with EMA® Electronic Health Records System

November 04, 2021

From Castle Biosciences, Inc.

Via Business Wire

DecisionDx®-Melanoma Integrated Test Result Now Includes i31-GEP for Risk of Recurrence

October 28, 2021

From Castle Biosciences, Inc.

Via Business Wire

New Data Demonstrating Accuracy of DecisionDx® DiffDx™-Melanoma Presented at ASDP 58th Annual Meeting

October 26, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Release Third Quarter 2021 Financial Results and Host Conference Call on Monday, Nov. 8, 2021

October 25, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences Presents Data from Suite of Dermatologic Cancer Genomic Tests at Fall Clinical Dermatology Conference 2021

October 22, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences to Acquire Cernostics

October 19, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences President and CEO Derek Maetzold Will Deliver Keynote Presentation During Arizona Bioscience Week

September 28, 2021

From Castle Biosciences, Inc.

Via Business Wire

Castle Biosciences's Return On Capital Employed Overview ↗

September 16, 2021

Castle Biosciences (NASDAQ:CSTL) brought in sales totaling $22.76 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 105.65%, resulting in a...

Via Benzinga

Castle Biosciences Announces New York Approval of DecisionDx® DiffDx™-Melanoma

September 16, 2021

From Castle Biosciences

Via Business Wire

Castle Biosciences Recognized as a Top 100 Healthcare Technology Company of 2021

August 30, 2021

From Castle Biosciences, Inc.

Via Business Wire

< Previous 1 2

...

7 8 9 10 11 12 13 14 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.